Insulin-like growth factor binding protein-3-dependent signaling may be viewed as a controversial target for cancer therapy, since in some cancers IGFBP3 appears to act as a tumor suppressor gene, but our data suggest the plausibility of this approach for women with TNBC. The gene discussed is IGFBP3; the disease is cancer.